CXC chemokine ligand 16, inversely correlated with CD99 expression in Hodgkin Reed-Sternberg cells, is widely expressed in diverse types of lymphomas

Liu,Fang; Zhang,Yu; Tang,Hongping; Zhou,Xinhua; Wu,Ziqing; Tang,Dongsheng; Zhao,Tong

doi:10.3892/or.2013.2522

CXC chemokine ligand 16, inversely correlated with CD99 expression in Hodgkin Reed-Sternberg cells, is widely expressed in diverse types of lymphomas

Authors:
- Fang Liu
- Yu Zhang
- Hongping Tang
- Xinhua Zhou
- Ziqing Wu
- Dongsheng Tang
- Tong Zhao
View Affiliations

Affiliations: Department of Basic Medical Sciences, Medical School, Foshan University, Foshan, Guangdong 528000, P.R. China, Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: June 5, 2013 https://doi.org/10.3892/or.2013.2522
Pages: 783-792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study examined a correlation between CXC chemokine ligand 16 (CXCL16) and cell differentiation antigen 99 (CD99) expression and investigated the role of CXCL16 in human lymphoma cell lines and clinical samples. Cytokine antibody arrays were used to measure the differentially expressed cytokines in tumor tissues. The expression of CXCL16 and CD99 was analyzed by quantitative PCR (qPCR) and western blotting, while the pathways involved were assessed by western blotting and enzyme-linked immunosorbent assay (ELISA). The expression of CXCL16 was investigated in 9 lymphoma cell lines (L428, RPMI-8226, KM3, Jurkat, OCI-Ly1, OCI-Ly8, OCI-Ly10, Karpass299 and Raji) as well as in clinical lymphoma samples using qPCR, western blotting and immunochemistry. Soluble CXCL16 (sCXCL16) levels were measured by ELISA and proliferation was analyzed by CCK‑8 proliferation assays. CXCL16 was one of the upregulated chemokines when lymphoma cells where transferred from in vitro to in vivo conditions. The increased expression and secretion of CXCL16 paralleled with a decrease of mCD99L2 and was accompanied by NF-κB pathway activation and vice versa. CXCL16 was expressed in all 9 lymphoma cell lines with the highest levels in the Hodgkin lymphoma (HL) cell line L428, the plasma cell-derived cell lines RPMI‑8226 and KM3 and the T leukemia-derived cell line Jurkat. Higher levels of sCXCL16 were secreted by L428 cells, the diffuse large B-cell lymphoma (DLBCL)-derived cell lines (OCI-Ly1, OCI-Ly8 and OCI-Ly10) and Jurkat cells. CXCL16 was widely expressed in clinical samples of lymphoma patients with higher levels in HL compared to non-Hodgkin lymphoma. Human recombinant CXCL16 had no significant effect on L428 cell proliferation, but was able to stimulate CD4+ T lymphocytes to proliferate. CXCL16, inversely correlated with CD99 expression in Hodgkin Reed-Sternberg (H/RS) cells, is widely expressed in diverse types of lymphomas.

View Figures

View References

1	Aggarwal BB, Shishodia S, Sandur SK, et al: Inflammation and cancer: how hot is the link? Biochem Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
2	O’Hayre M, Salanga CL, Handel TM, et al: Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 409:635–649. 2008.PubMed/NCBI
3	Yamashita H, Takahashi Y, Kano T, et al: Malignant lymphoma presenting as inflammation of unknown origin. Nihon Rinsho Meneki Gakkai Kaishi. 35:136–143. 2012.(In Japanese).
4	Aldinucci D, Gloghini A, Pinto A, et al: The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumor growth and immune escape. J Pathol. 221:248–263. 2010.
5	Küppers R: The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 9:15–27. 2009.
6	Kim SH, Choi EY, Shin YK, et al: Generation of cells with Hodgkin’s and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Blood. 92:4287–4295. 1998.
7	Kim SH, Shin YK, Lee IS, et al: Viral latent membrane protein1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin’s and Reed-Sternberg phenotype. Blood. 95:294–300. 2000.
8	Huang X, Zhou X, Wang Z, et al: CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation. Int J Cancer. 131:E382–E394. 2012. View Article : Google Scholar : PubMed/NCBI
9	Suh YH, Shin YK, Kook MC, et al: Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene. 307:63–76. 2003. View Article : Google Scholar
10	Liu F, Zhang G, Liu F, et al: Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo. Oncol Rep. 29:1405–1414. 2013.PubMed/NCBI
11	Matloubian M, David A, Engel S, et al: A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol. 1:298–304. 2000. View Article : Google Scholar : PubMed/NCBI
12	Wilbanks A, Zondlo SC, Murphy K, et al: Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol. 166:5145–5154. 2001. View Article : Google Scholar : PubMed/NCBI
13	Hundhausen C, Schulte A, Schulz B, et al: Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol. 178:8064–8072. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ruth JH, Haas CS, Park CC, et al: CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 54:765–778. 2006. View Article : Google Scholar : PubMed/NCBI
15	Morgan AJ, Guillen C, Symon FA, et al: Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy. 35:1572–1580. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sheikine Y, Bang CS, Nilsson L, et al: Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis. 188:462–466. 2006. View Article : Google Scholar : PubMed/NCBI
17	Li X, Conklin L and Alex P: New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 14:5115–5124. 2008. View Article : Google Scholar
18	Verbeke H, Struyf S, Laureys G, et al: The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ha HK, Lee W, Park HJ, et al: Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol Med Rep. 4:419–424. 2011.PubMed/NCBI
20	Guo L, Cui ZM, Zhang J, et al: Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. Chin J Cancer. 30:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
21	Taghizadeh R, Noh M, Huh YH, et al: CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One. 5:e151832010. View Article : Google Scholar : PubMed/NCBI
22	Darash-Yahana M, Gillespie JW, Hewitt SM, et al: The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One. 4:e66952009. View Article : Google Scholar : PubMed/NCBI
23	Feng MJ, Qiu C, Lai YJ, et al: Application of immunomagnetic screening strategy for separation of CD4⁺and CD8⁺T cell subpopulations of peripheral blood. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 13:205–209. 2005.(In Chinese).
24	Zhang Y, Li XZ, Wen ZH, et al: Relationship between lymphocyte immunophenotypes and histologic subtypes of Hodgkin’s lymphoma and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 17:888–893. 2009.(In Chinese).
25	Bracci PM, Skibola CF, Conde L, et al: Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma. 51:497–506. 2010. View Article : Google Scholar : PubMed/NCBI
26	Aldinucci D, Lorenzon D, Cattaruzza L, et al: Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 122:769–776. 2008. View Article : Google Scholar : PubMed/NCBI
27	Hnátková M, Mociková H, Trnený M, et al: The biological environment of Hodgkin’s lymphoma and the role of the chemokine CCL17/TARC. Prague Med Rep. 110:35–41. 2009.
28	Wente MN, Gaida MM, Mayer C, et al: Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol. 33:297–308. 2008.PubMed/NCBI
29	Hu W, Zhen X, Xiong B, et al: CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 99:1362–1369. 2008. View Article : Google Scholar : PubMed/NCBI
30	Matsushita K, Toiyama Y, Tanaka K, et al: Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol. 19(Suppl 3): S518–S527. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hanamoto H, Nakayama T, Miyazato H, et al: Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin’s disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol. 164:997–1006. 2004.PubMed/NCBI
32	Deng I, Chen N, Li Y, et al: CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta. 1806:42–49. 2010.PubMed/NCBI
33	Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al: The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 52:1913–1919. 2011. View Article : Google Scholar : PubMed/NCBI
34	Matsumura S, Wang B, Kawashima N, et al: Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 181:3099–3107. 2008. View Article : Google Scholar : PubMed/NCBI
35	Machado L, Jarrett R, Morgan S, et al: Expression and function of T cell homing molecules in Hodgkin’s lymphoma. Cancer Immunol Immunother. 58:85–94. 2009.